Table 1 Demographic, clinical and biological data of the patients at baseline
From: Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
Variables | MTX active (n= 13) (mean ± SD) | Responders (n= 23) (mean ± SD) | Non-responders (n= 12) (mean ± SD) | P-value |
|---|---|---|---|---|
Age (years) | 51.64 ± 10.88 | 50.36 ± 5.82 | 52.25 ± 11.09 | .762 |
Sex (men/women) | 38.46%/61.54% | 33.33%/66.67% | 37.50%/62.50% | .809 |
CRP (mg/dl) | 16.61 ± 7.21 | 14.33 ± 14.10 | 11.68 ± 10.74 | .569 |
Rheumatoid factor (+/-) | 92.30%/7.70 | 80.00%/20.00% | 62.50%/37.50 | .283 |
Anti-CCP (UI/ml) | 423.25 ± 296.01 | 994.60 ± 620.24 | 329.50 ± 7.50 | .075 |
DAS28 | 3.71 ± .71 | 2.64 ± .84 | 3.20 ± .88 | .090 |
Erosions (+/-) | 30.76%/69.24% | 60.00%/40.00% | 71.40%/28.60% | .518 |
Onset of Symptoms (months) | 9.60 ± 9.10 | 100.53 ± 66.14 | 148.14 ± 77.79 | .090 |
HAQ | .78 ± .53 | 1.18 ± .47 | 1.31 ± .72 | .553 |